Immunoglobulin News and Research

RSS

CSL Behring strengthens global manufacturing capabilities to meet demand for lifesaving therapies

CSL Behring today announced a multi-year, $450 million two-site global capacity expansion – the latest in a series of recent production expansions to meet the growing need for its lifesaving and life-improving therapies that are used to treat patients with rare and serious medical disorders around the world.

8 Oct 2014

NCI awards $1.4M grant to Advanced Cell Diagnostics to develop diagnostic test for B-cell NHLs

Advanced Cell Diagnostics, Inc. (ACD), a global technology and market leader in in situ nucleic acid detection for life science research and clinical diagnostics, has been awarded a two-year, $1.4 million grant from National Cancer Institute (NCI) under its SBIR Phase II Program.

From Advanced Cell Diagnostics 7 Oct 2014

Yale University researchers identify bacterial culprits that drive IBD

Yale University researchers have identified a handful of bacterial culprits that may drive inflammatory bowel diseases (IBD) such as Crohn's disease and ulcerative colitis, using patients' own intestinal immune responses as a guide.

29 Aug 2014

Vaccine boosts advanced NSCLC patient survival

Investigation of a vaccine targeting a glycoside present in non-small-cell lung cancer has demonstrated efficacy as a switch therapy for patients with stable, advanced disease after chemotherapy.

28 Aug 2014

TIM-family proteins also have ability to block release of HIV and other viruses

A family of proteins that promotes virus entry into cells also has the ability to block the release of HIV and other viruses, University of Missouri researchers have found.

26 Aug 2014

Blood test could help gauge psychosis risk

Researchers have developed a multiplex blood assay that may aid the identification of high-risk individuals who will progress to psychosis.

21 Aug 2014

Newborn screening for SCID holds promise that affected children can lead healthy lives

Using population-based screening outcomes of approximately 3 million infants, a team of scientists across 14 states, including four researchers at the University of Massachusetts Medical School, have shown that newborn screening for severe combined immunodeficiency (SCID) can be successfully implemented across public health newborn screening programs.

21 Aug 2014

Choroidal consequences differ between anti-VEGF therapies

Aflibercept’s possession of a fragment crystallisable region may make it more likely to induce unwanted effects in retinal and choroidal vessels than other anti-vascular endothelial growth factor therapies, say researchers.

20 Aug 2014

Newborn screening indicates that incidence of SCID is higher than previously believed

Newborn screening performed in numerous states indicates that the incidence of the potentially life-threatening disorder, severe combined immunodeficiency, is higher than previously believed, at 1 in 58,000 births, although there is a high rate of survival, according to a study in the August 20 issue of JAMA.

20 Aug 2014

Young inner-city children appear to suffer from food allergies

Already known for their higher-than-usual risk of asthma and environmental allergies, young inner-city children appear to suffer disproportionately from food allergies as well, according to results of a study led by scientists at the Johns Hopkins Children's Center.

15 Aug 2014

Food allergies more common in young inner-city children

15 Aug 2014

New method could make cashews safer for people with allergies

For the millions of adults and children in the U.S. who have to shun nuts to avoid an allergic reaction, help could be on the way. Scientists are now developing a method to process cashews - and potentially other nuts - that could make them safer to eat for people who are allergic to them.

11 Aug 2014

Localised inflammation found in eosinophilic otitis media

Antigen-specific immunoglobulin E is produced locally in the middle ear mucosa of patients with eosinophilic otitis media, clinical research indicates.

15 Jul 2014

Biotest Pharmaceuticals opens new plasma collection center in Valdosta, Georgia

Biotest Pharmaceuticals Corporation, a leading developer of immunology biotherapeutic products, is pleased to announce the addition of its newest plasma collection center located at 311 North Patterson Road, in Valdosta, Georgia.

2 Jul 2014

Inovio announces positive results on DNA-based monoclonal antibody therapy targeting CHIKV

Inovio Pharmaceuticals, Inc. announced today that its novel DNA-based therapeutic monoclonal antibody targeting Chikungunya virus (CHIKV) completely protected mice from a lethal CHIKV challenge.

27 May 2014

Peptide antibodies hit immune-response-stifling MDSCs without harming other vital cells

Scientists have found a way to target elusive cells that suppress immune response, depleting them with peptides that spare other important cells and shrink tumors in preclinical experiments, according to a paper published online by Nature Medicine.

26 May 2014

Sanofi presents Phase II trial results for investigational vaccine for prevention of CDI

Sanofi Pasteur, the vaccines division of Sanofi, presented Phase II (H-030-012) trial results for an investigational vaccine for the prevention of Clostridium difficile infection at the 114th General Meeting of the American Society for Microbiology.

20 May 2014

Shark antibodies reveal evolutionary principles of immunoglobulins

Custom-tailored antibodies are regarded as promising weapons against a multitude of serious illnesses. Since they can accurately recognize specific structures on the surface of viruses, bacteria or cancer cells, they are already being deployed successfully in cancer diagnostics and therapy, as well as against numerous other diseases. The stability of the sensitive antibodies is a decisive factor in every step, from production and storage to therapeutic application.

15 May 2014

Single-cell genomics study confirms that immune cells produce steroids

Researchers at the European Bioinformatics Institute (EMBL-EBI) and the Wellcome Trust Sanger Institute have discovered that some immune cells turn themselves off by producing a steroid.

9 May 2014

Emergent BioSolutions reports total revenue of $53.9 million for Q1 2014

Emergent BioSolutions Inc. reported total revenue for Q1 2014 of $53.9 million as compared to $43.1 million in 2013. In addition, Q1 2014 net loss was $20.2 million, or $0.55 per share, as compared to a net loss of $8.1 million, or $0.22 per share, in 2013.